<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654313</url>
  </required_header>
  <id_info>
    <org_study_id>D4920C00001</org_study_id>
    <nct_id>NCT03654313</nct_id>
  </id_info>
  <brief_title>Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, PK and immunogenicity of single and multiple ascending
      doses of MEDI6570 in subjects with Type 2 Diabetes Mellitus
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and
      Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2
      Diabetes Mellitus
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">July 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6570</measure>
    <time_frame>Day 1 - Day 190 (Part A); Day 1 - Day 250 (Part B)</time_frame>
    <description>Measured by the incidence of treatment- emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6570 AUC</measure>
    <time_frame>Day 1 - Day 190 (Part A); Day 1 - Day 250 (Part B)</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6570 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6570 Cmax</measure>
    <time_frame>Day 1 - Day 190 (Part A); Day 1 - Day 250 (Part B)</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6570 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6570 Tmax</measure>
    <time_frame>Day 1 - Day 190 (Part A); Day 1 - Day 250 (Part B)</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6570 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6570 Terminal Half life</measure>
    <time_frame>Day 1 - Day 190 (Part A); Day 1 - Day 250 (Part B)</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6570 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity rate</measure>
    <time_frame>Day 1 - Day 190 (Part A); Day 1 - Day 250 (Part B)</time_frame>
    <description>ADA incidence rate and titer will be tabulated for each treatment group. Samples confirmed positive for ADA will be tested and analyzed for nAB titer and summarized similarly.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Part A MEDI6570 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A MEDI6570 Cohort 1 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A MEDI6570 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A MEDI6570 Cohort 2 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A MEDI6570 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A MEDI6570 Cohort 3 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A MEDI6570 Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A MEDI6570 Cohort 4 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MEDI6570 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B MEDI6570 Cohort 1 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MEDI6570 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B MEDI6570 Cohort 2 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MEDI6570 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part B MEDI6570 Cohort 3 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part B Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A MEDI6570 Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A MEDI6570 Cohort 5 Dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A MEDI6570 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A MEDI6570 Cohort 6 dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI6570</intervention_name>
    <description>MEDI6570</description>
    <arm_group_label>Part A MEDI6570 Cohort 1</arm_group_label>
    <arm_group_label>Part A MEDI6570 Cohort 2</arm_group_label>
    <arm_group_label>Part A MEDI6570 Cohort 3</arm_group_label>
    <arm_group_label>Part A MEDI6570 Cohort 4</arm_group_label>
    <arm_group_label>Part A MEDI6570 Cohort 5</arm_group_label>
    <arm_group_label>Part A MEDI6570 Cohort 6</arm_group_label>
    <arm_group_label>Part B MEDI6570 Cohort 1</arm_group_label>
    <arm_group_label>Part B MEDI6570 Cohort 2</arm_group_label>
    <arm_group_label>Part B MEDI6570 Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part A Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Part B Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Part B Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  In Part A, subjects aged 18 through 65 inclusive at screening. In Part B, male
             subjects aged 18 through 65 inclusive, and female subjects aged 40 to 65 inclusive, at
             screening.

          -  Body mass index of 18 to 45 kg/m2.

          -  Subjects with T2DM on stable medical therapy for at least 6 weeks prior to screening
             with no clinically significant dose change and/or new medications in the recent 6
             weeks

          -  Capable of giving written informed consent and adhere to visit/protocol schedule

          -  Female subjects must be of non-childbearing potential, confirmed at screening by one
             of the following: (a) Postmenopausal, defined as amenorrhea for ≥ 12 months following
             cessation of all exogenous hormonal treatments, and luteinizing hormone and follicle
             stimulating hormone (FSH) levels in the postmenopausal range. (b) Documentation of
             irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or
             bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical
             sterilization.

          -  Non-sterilized male subjects who are sexually active with a female partner of
             childbearing potential must use a male condom plus spermicide, and in addition the
             female partner must use 1 highly effective method of contraception.

          -  In Part B, subjects must meet CTA criteria as follows: (Estimated glomular filtration
             rate (eGFR) ≥ 60 mL/min/1.73m2. No allergy to iodinated contrast, no history of
             contrast induced nephropathy or no contraindication to beta blockers or nitroglycerin.
             No recent pulmonary embolism and must able to hold breath for at least 6 seconds. No
             history of coronary bypass surgery and no active arrhythmia on day of CTA scan (atrial
             fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions).

          -  For Part A Cohort 6, subjects must be Japanese (eg, natives of Japan or Japanese
             Americans), defined as having both parents and four grandparents who are Japanese.
             This includes second and third generation subjects of Japanese descent whose parents
             or grandparents are living in a country other than Japan.

        Exclusion Criteria

          -  History of any clinically important disease or disorder (not including T2DM) which, in
             the opinion of the investigator, may either put the subject at risk because of
             participation in the study, or influence the results or the subject's ability to
             participate in the study.

          -  History or presence of hepatic or renal disease, or any other condition known to
             interfere with absorption, distribution, metabolism or excretion of drugs.

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             of the first administration of investigational product, or planned surgical procedure
             before study completion.

          -  Female subjects who are pregnant and/or currently lactating.

          -  Any clinically important abnormalities in clinical chemistry, hematology, coagulation
             parameters, or urinalysis results -History of blood dyscrasia, hemostatic disorder,
             systemic bleeding, or prior trauma that places the subject at a higher risk of
             bleeding.

          -  History of vascular abnormalities including aneurysms, prior dissections; hx of severe
             hemorrhage, hematemesis, melena, haemoptysis, severe epistaxis, severe
             thrombocytopenia, intracranial hemorrhage, rectal bleeding, or major surgery/procedure
             within 3 months prior to Visit 1; a history suggestive of active peptic ulcer disease;
             or prior intracranial haemorrhage. -Dual-antiplatelet therapy, anticoagulation therapy
             or thrombolytic use, in the past month or planned use during the duration of the
             study. -Chronic aspirin therapy or chronic NSAID therapy.

          -  Clinically significant ECG that may interfere with the interpretation of serial ECG
             and QT interval changes screening. -Persistent or intermittent complete bundle branch
             block, incomplete bundle branch block, or intraventricular conduction delay with QRS &gt;
             110 ms. Subjects with QRS &gt; 110 ms but &lt; 115 ms are acceptable if there is no evidence
             of ventricular hypertrophy or pre excitation. -Abnormal vital signs

          -  Hemoglobin A1c&gt;9.0% measured at screening. HbA1c can be retested once after
             approximately 4 weeks.

          -  Clinically significant late diabetic complications including symptoms consistent with
             angina, congestive heart failure, and peripheral arterial disease (claudication), or
             other complications such as proliferative retinopathy, maculopathy, or gastroparesis.

          -  Any positive result at screening for serum hepatitis B surface antigen, hepatitis C
             antibody, or human immunodeficiency virus (HIV).

          -  History of cancer in the last 5 years, with the exception of non-melanoma skin cancer.
             -History of alcohol substance abuse within the past 6 months. A positive drug screen
             including recreational marijuana will be exclusionary. However, subjects with a
             documented medical need or prescription may be included at the discretion of the
             principal investigator.

          -  History of hypersensitivity or ongoing severe allergy or history of hypersensitivity
             to drugs with a similar chemical structure or calss to MEDI6570.

          -  History of ongoing infection or febrile illness within 30 days prior to Day 1.

          -  Current or previous use of systemic corticosteroids within 28 days prior to screening.

          -  Receipt of any investigational product or use of any biologics within 6 months or 5
             half lives prior to screening (whichever is longer), or planned participation in an
             additional study of an investigational product therapy or biologic prior to end of
             follow up period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin Sinsakul</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>CAD</keyword>
  <keyword>Atherosclerotic Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

